A Trial to Investigate Relative Bioavailability of Three Different BI 1291583 Formulations Following Oral Administration at Two Dose Levels to Healthy Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Trial Consisting of 2 Parts)
Latest Information Update: 26 May 2025
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 18 May 2025 Status changed from active, no longer recruiting to completed.
- 02 Apr 2025 Planned End Date changed from 10 Mar 2025 to 30 Apr 2025.
- 18 Feb 2025 Planned End Date changed from 14 Feb 2025 to 10 Mar 2025.